Professional
Added to YB: 2024-05-30
Pitch date: 2024-03-31
VCEL [bullish]
Vericel Corporation
-30.53%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Market Cap
$2.0B
Pitch Price
$52.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
67.92
P/E
161.63
EV/Sales
7.65
Sector
Biotechnology
Category
growth
Show full summary:
Conestoga Capital Advisors Small Cap Composite Portfolio Holding: Vericel Corporation
VCEL: Surged 46% as MACI cartilage repair grows 20%+. Arthroscopic option expands market. Burn care accelerating with Nexobrid launch to remove eschar. Raised 2024 margin guidance on strong growth.
Read full article (1 min)